ABB to Invest €100 Million in Global Innovation and Training Campus
One year after announcing its acquisition of B&R (Bernecker + Rainer Industrie-Elektronik GmbH), ABB is to invest €100 million in Austria to build a state-of-the-art innovation and training campus at the home of B&R in Eggelsberg, Upper Austria. It is the largest organic investment in industrial automation in ABB’s more than 130-year history and lays the foundation for around 1,000 new high-tech jobs in Austria.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180406005249/en/
ABB to invest €100 million in global innovation and training campus in Austria (Graphic: Business Wire)
The new innovation and training campus will develop technologies for the factory of the future, based on ABB AbilityTM, in which production will be undertaken autonomously by smart and cloud-connected machines and robots. With this investment, ABB is delivering on its Next Level strategy, which defines innovation as a key driver of profitable growth. The company invests $1.4 billion in R&D annually, and has a team of around 30,000 R&D and application engineers. B&R has more than 1,000 employees working in R&D and application development.
The new research and development campus will cover 35,000 m² and be home to a significant number of state-of-the-art facilities. Alongside ultra-modern R&D laboratories, which will develop and test new automation technologies, from industrial control systems up to machine learning and artificial intelligence, there will be an Automation Academy to train and educate customers, partners and employees in these technologies. The ground-breaking ceremony is planned for this summer, and the new campus is expected to be up and running in the course of 2020. Once complete, the Eggelsberg site will be one of ABB’s largest research and development centers.
With the new campus, the world’s second-largest provider of industrial automation solutions will further expand its leadership position in machine and factory automation. The development of disruptive technologies will enable ABB to better serve the highly attractive $20-billion machine and factory automation market segment.
ABB acquired B&R, then the largest independent provider of product- and software-based open-architecture solutions for machine and factory automation worldwide, in July 2017. Today, B&R is integrated into ABB’s Industrial Automation division as its global Machine & Factory Automation business unit. With the combined portfolios, ABB is today the only industrial automation provider offering customers the entire spectrum of technology and software solutions around measurement, control, actuation, robotics, electrification and digitalization.
“B&R has had an excellent start within ABB and has exceeded our expectations. We are well on track to achieve our goal of revenues of more than $1 billion soon,” said ABB CEO Ulrich Spiesshofer, at a press conference in Linz with the Austrian Chancellor, Sebastian Kurz. “With our €100 million investment, we are strengthening this dynamic and the pillars of this success story: innovation and people. In addition to the new research and development capacity, our investment will expand B&R’s Automation Academy, offering customers, partners and employees globally unique education and training programs.”
“With this clear commitment to the Eggelsberg location, ABB has established itself as the market leader in automation in Austria,” said Chancellor Sebastian Kurz. “True to its word, the company is now making an investment that is of tremendous importance to Austria as a business location of international standing. This is the starting signal for a location offensive in the key segment of digital industry. It is an important impulse for the creation of highly qualified new jobs and the positioning of Austria as a high-tech location.”
This will also be beneficial for the country`s educational landscape. “Further strengthening our good relationships with universities, universities of Applied Sciences and higher technical education institutes is part of our innovation and research strategy. This way we can further accelerate our speed of growth and innovation as well as extend our technology leadership,” said Hans Wimmer, Managing Director of B&R.
“This is a great day for B&R,” said Josef Rainer, Co-founder of Bernecker & Rainer Industrie-Elektronik GmbH. “The smooth integration shows that the company Erwin Bernecker and I founded 39 years ago is in excellent hands. I am delighted that ABB continues to write and accelerate our success story with this historic investment.”
ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader in electrification products, robotics and motion, industrial automation and power grids, serving customers in utilities, industry and transport & infrastructure globally. Continuing a history of innovation spanning more than 130 years, ABB today is writing the future of industrial digitalization with two clear value propositions: bringing electricity from any power plant to any plug and automating industries from natural resources to finished products. As title partner of Formula E, the fully electric international FIA motorsport class, ABB is pushing the boundaries of e-mobility to contribute to a sustainable future. ABB operates in more than 100 countries with about 135,000 employees. www.abb.com
Note: This is a translation of the German press release of ABB from April 6, 2018, available at www.abb.com/news. In case of discrepancies, the original German version applies.
Phone: +41 43 317 7111
Phone: +41 43 317 71 11
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AURAK Gains SACSCOC Accreditation15.12.2018 10:49 | Pressemelding
The Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) officially announced the accreditation of the American University of Ras Al Khaimah (AURAK) at its 2018 Annual Meeting which was held in New Orleans, Louisiana, in the United States of America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181215005017/en/ AURAK delegation during the SACSCOC conference in New Orleans” (Photo: AETOSWire) SACSCOC, the regional body for the accreditation of degree-granting higher education institutions in the Southern United States, has a membership of more than 800 institutions in the Southern states and other international sites approved by SACSCOC that award associate, baccalaureate, master’s, and/or doctoral degrees. SACSCOC also awards accreditation to other international institutions of higher education that satisfy all its requirements and demonstrate compliance with its accreditation standards. AURAK now
Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 17:41 | Pressemelding
Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 17:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl
Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 15:42 | Pressemelding
Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00
Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 14:00 | Pressemelding
Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu
Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 09:07 | Pressemelding
Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha